‌

Actions

Action Type

‌
‌

AI Mode

Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.

Ask AI

Overview

Detailed Summary

Mankind Pharma Limited is a leading Indian pharmaceutical company engaged in manufacturing and marketing a broad spectrum of pharmaceutical products and healthcare solutions. The company operates in both acute and chronic therapeutic areas, with a notable presence in cardiovascular, anti-diabetic, and neuro/CNS segments.
In Q3 FY26, Mankind Pharma reported a revenue increase of 11.5% YoY, driven by strong domestic pharmaceutical performance. Adjusted EBITDA margins improved to 25.9%, showcasing robust operational efficiency.
The expansion into specialty and super specialty segments via BSV acquisition has marked significant growth, with BSV now contributing substantially to Mankind's revenue and offering a high entry barrier to competitors.
Mankind Pharma's consumer healthcare segment showed resilience with a 5.2% growth in Q3 FY26, bolstered by high-performing brands like Gas-O-Fast and Manforce, and increasing contributions from e-commerce and modern trade channels.
Strategic transformations in workforce and operational strategies have bolstered Mankind's foundation, positioning it for sustainable long-term growth and enhanced market position across its pharma and consumer healthcare segments.

Sector: Pharmaceuticals
Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln Lrg
Market Cap: 85,050 Cr
Volatility: Low Risk
P/E Ratio: 45.8
Industry P/E: 26.2
PEG Ratio: 1.8
P/B Ratio: 5.6
52W High: 2,726.75
52W Low: 2,029.35

Sales CAGR

1Y: 18.98%
3Y: 8.26%
5Y: 14.65%
10Y: —

Profit CAGR

1Y: 3.57%
3Y: 10.69%
5Y: 14.48%
10Y: —

ROE

TTM: 11.45%
3Y: 15.78%
5Y: 17.38%
10Y: —

ROCE

TTM: 12.34%
3Y: 17.21%
5Y: 20.05%
10Y: —

Technicals

‌

Forecasts

Unlock Premium Features

Analyst Target, Price, EPS and Revenue Projections

Upgrade

Peers

Symbol	Price	Market Cap	P/E	P/B	Div Yield (%)	ROE (%)	ROCE (%)	ROA (%)
CIPLA	1331.70	1,07,503 Cr	22.62	3.27	1.20	16.53	21.05	11.32
DRREDDY	1268.60	1,05,798 Cr	19.01	2.94	0.63	16.03	18.66	10.16
LUPIN	2199.20	1,00,496 Cr	20.20	5.12	0.55	22.03	21.92	13.94
ZYDUSLIFE	904.80	91,049 Cr	17.80	3.60	1.22	19.44	19.08	10.52
MANKIND	2060.60	85,050 Cr	45.78	5.56	0.00	11.45	12.34	6.26
AUROPHARMA	1155.45	66,705 Cr	19.00	1.90	0.00	9.77	12.69	6.63
ALKEM	5400.00	64,584 Cr	27.47	4.84	0.83	17.69	18.13	11.95

Financial Statements

AI Powered Summary

Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.

Ask AI

Consolidated Quarterly Results (in ₹ Crores)

View Standalone

Total Figures

QoQ Changes

Total Figures

	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025
Sales	2,708	2,607	2,441	2,893	3,077	3,230	3,079	3,570	3,697	3,567
Expenses	2,025	2,000	1,850	2,212	2,226	2,400	2,396	2,724	2,776	2,648
Operating Profit	683	607	591	682	850	830	683	847	921	919
OPM %	25.21	23.27	24.21	23.56	27.63	25.69	22.19	23.72	24.92	25.77
Other Income	63	75	95	105	112	81	254	83	94	-31
Interest	8.62	9.19	9.38	11	7.10	221	191	171	170	157
Depreciation	96	110	105	108	106	192	231	219	222	223
Profit Before Tax	641	562	572	668	849	497	515	540	624	509
Tax %	20.25	18.23	16.62	18.66	22.42	22.68	16.77	17.74	16.64	18.69
Net Profit	511	460	477	543	659	385	429	445	520	414
EPS in Rs	12.12	10.98	11.39	12.98	15.80	9.43	10.17	10.60	12.38	9.89

Consolidated Profit Loss (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	TTM
Sales	5,865	6,214	7,782	8,749	10,335	12,207	12,279
Expenses	4,428	4,566	5,792	6,849	7,800	9,190	9,235
Operating Profit	1,437	1,648	1,989	1,901	2,535	3,018	3,045
OPM %	24.50	26.52	25.56	21.72	24.53	24.72	24.80
Other Income	122	183	210	141	296	549	551
Interest	22	20	59	44	34	429	429
Depreciation	99	119	167	326	398	621	637
Profit Before Tax	1,438	1,692	1,975	1,671	2,399	2,516	2,530
Tax %	26.54	23.56	26.42	21.63	19.07	20.26	20.33
Net Profit	1,056	1,293	1,453	1,310	1,942	2,007	2,015
EPS in Rs	—	—	—	31.48	46.27	48.39	43.04
Dividend Payout %	0.00	24.06	0.00	0.00	0.00	0.00	—

Consolidated Balance Sheet (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Equity Capital	40	40	40	40	40	41
Reserves	3,445	4,682	6,115	7,395	9,323	14,291
Borrowings	131	241	873	170	207	8,511
Other Liabilities	1,457	1,410	2,119	2,110	2,393	4,916
Total Liabilities	5,073	6,373	9,148	9,715	11,963	27,760
Fixed Assets	1,594	1,659	3,583	4,245	4,540	19,004
CWIP	317	372	701	550	282	826
Investments	835	1,517	1,115	1,352	2,573	2,042
Other Assets	2,327	2,824	3,749	3,568	4,568	5,887
Total Assets	5,073	6,373	9,148	9,715	11,963	27,760

Consolidated Cash Flows (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Cash from Operating Activity	1,070	1,137	920	1,813	2,152	2,413
Cash from Investing Activity	-439	-1,222	-1,369	-1,054	-2,082	-12,625
Cash from Financing Activity	-531	-7.81	605	-740	5.27	10,233
Net Cash Flow	100	-93	155	19	76	21

Shareholdings

Shareholding History

Quarterly

Yearly

Quarterly

	May 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025
Promoters	76.50%	76.50%	76.50%	76.50%	74.88%	74.87%	74.87%	72.71%	72.70%	72.68%	72.67%	72.66%
FIIs	2.61%	4.18%	4.18%	6.74%	9.87%	11.58%	12.37%	13.35%	12.92%	13.07%	12.84%	11.34%
DIIs	2.64%	4.64%	4.56%	9.79%	11.14%	9.95%	9.90%	11.02%	11.48%	11.50%	11.92%	13.25%
Public	18.25%	14.68%	14.76%	6.97%	4.11%	3.61%	2.86%	2.92%	2.90%	2.75%	2.57%	2.75%
Total Shareholders	4,02,322	1,31,918	1,34,731	1,27,449	1,35,116	1,53,450	1,63,854	1,72,431	1,80,597	1,79,549	1,70,347	1,77,539

Market Transactions

Unlock Premium Features

Analyst Target, Price, EPS and Revenue Projections

Upgrade

Projection

Unlock Premium Features

Get In-depth insights on EPS and Revenue forecasts

Upgrade

Documents

Presentations

Concalls

Reports

Presentations

Investor Presentation

Q3 FY26

Investor Presentation

Q2 FY26

Investor Presentation

Q1 FY26

Investor Presentation

Q4 FY25

Available on Pro Plan

Unlock reports, presentations, and AI-powered insights.

Investor Presentation

Q3 FY25

Available on Pro Plan

Unlock reports, presentations, and AI-powered insights.

Investor Presentation

Q2 FY25

Available on Pro Plan

Unlock reports, presentations, and AI-powered insights.

Investor Presentation

Q1 FY25

Available on Pro Plan

Unlock reports, presentations, and AI-powered insights.

Investor Presentation

Q1 FY25

Showing 1 - 8 of 17

Actions

Action Type

‌
‌

Announcements

Last 7 days

Newest

Sentiment

Regulatory Filing

6 days ago

Search and Seizure at Bharat Serums and Vaccines

Disclosure of a search and seizure operation by the GST Department at Bharat Serums and Vaccines Limited, a subsidiary of Mankind Pharma, conducted from February 3-8, 2026.

Concall Transcript

6 days ago

Q3 & 9M FY26 Earnings Call Transcript

Transcript of Mankind Pharma's Q3 and 9M FY26 earnings conference call held on February 3, 2026, detailing significant revenue growth and business performance.

AI Mode

Ask AI

Frequently Asked Questions about Mankind Pharma Ltd

Mankind Pharma Ltd (MANKIND) is currently trading at 2,060.60 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Mankind Pharma Limited is a leading Indian pharmaceutical company engaged in manufacturing and marketing a broad spectrum of pharmaceutical products and healthcare solutions. The company operates in both acute and chronic therapeutic areas, with a notable presence in cardiovascular, anti-diabetic, and neuro/CNS segments. In Q3 FY26, Mankind Pharma reported a revenue increase of 11.5% YoY, driven by strong domestic pharmaceutical performance. Adjusted EBITDA margins improved to 25.9%, showcasing robust operational efficiency. The expansion into specialty and super specialty segments via BSV acquisition has marked significant growth, with BSV now contributing substantially to Mankind's revenue and offering a high entry barrier to competitors. Mankind Pharma's consumer healthcare segment showed resilience with a 5.2% growth in Q3 FY26, bolstered by high-performing brands like Gas-O-Fast and Manforce, and increasing contributions from e-commerce and modern trade channels. Strategic transformations in workforce and operational strategies have bolstered Mankind's foundation, positioning it for sustainable long-term growth and enhanced market position across its pharma and consumer healthcare segments.

Over the past 52 weeks, Mankind Pharma Ltd has traded between a low of ₹2,029.35 and a high of ₹2,726.75. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Mankind Pharma Ltd has a market capitalization of approximately 85,050.23. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Mankind Pharma Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 45.78 and operates in the Pharmaceuticals sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 85,050.23 Cr, Mankind Pharma Ltd is classified as a Mid Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Mankind Pharma Ltd operates in the Pharmaceuticals sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Mankind Pharma Ltd is 45.78. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

The most significant announcement is the 'Biopharma Shakti' scheme, with a ₹10,000 crore outlay over five years to promote domestic manufacturing of biologics and biosimilars, directly benefiting R&D-focused companies like Mankind Pharma.

Mankind Pharma Ltd

Actions

AI Mode

Ask AI

Utility

Company

Overview

Financial Ratios

Technicals

Forecasts

Unlock Premium Features

Upgrade

Peers

Price Chart Comparison

Financial Statements

AI Powered Summary

Ask AI

Consolidated Quarterly Results (in ₹ Crores)

Consolidated Profit Loss (in ₹ Crores)

Consolidated Balance Sheet (in ₹ Crores)

Consolidated Cash Flows (in ₹ Crores)

Shareholdings

Shareholding History

Market Transactions

Unlock Premium Features

Upgrade

Projection

Unlock Premium Features

Upgrade

Documents

Actions

Announcements

Search and Seizure at Bharat Serums and Vaccines

Q3 & 9M FY26 Earnings Call Transcript

AI Mode

Ask AI

Frequently Asked Questions about Mankind Pharma Ltd

What is Mankind Pharma Ltd share price today?

What does Mankind Pharma Ltd do?

What is the 52-week high and low of Mankind Pharma Ltd?

What is the market capitalization of Mankind Pharma Ltd?

Should I consider investing in Mankind Pharma Ltd stock?

Is Mankind Pharma Ltd a large-cap, mid-cap, or small-cap stock?

Which sector does Mankind Pharma Ltd belong to and why does it matter?

What is the PE ratio of Mankind Pharma Ltd?

What is the biggest announcement in Union Budget 2026 for Mankind Pharma?

Technicals

Documents

Oscillators

Neutral

Overall

Bearish

Moving Averages

Bearish

Overall

Bearish

Stock Summary and Key Metrics

Investment Checklist

Investment Checklist

Forecasts

Unlock Premium Features

Upgrade

Projection

Unlock Premium Features

Upgrade

Overview

Financial Ratios

Shareholdings

Shareholding History

Market Transactions

Unlock Premium Features

Upgrade

Peers

Price Chart Comparison

Investment Checklist

Financial Statements

AI Powered Summary

Ask AI

Consolidated Quarterly Results (in ₹ Crores)

Consolidated Profit Loss (in ₹ Crores)